Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.99 USD
+0.23 (5.98%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.98 -0.01 (-0.25%) 4:34 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Sutro Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 154 | 68 | 62 | 43 | 43 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 154 | 68 | 62 | 43 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 243 | 197 | 160 | 114 | 98 |
Income After Depreciation & Amortization | -89 | -129 | -99 | -71 | -55 |
Non-Operating Income | 12 | 16 | -4 | 43 | 4 |
Interest Expense | 11 | 3 | 3 | 4 | 4 |
Pretax Income | -89 | -117 | -106 | -32 | -56 |
Income Taxes | 18 | 3 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -107 | -119 | -106 | -32 | -56 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -107 | -119 | -106 | -32 | -56 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -92 | -124 | -91 | -66 | -52 |
Depreciation & Amortization (Cash Flow) | -2 | 5 | 8 | 5 | 3 |
Income After Depreciation & Amortization | -89 | -129 | -99 | -71 | -55 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.16 | 50.74 | 46.12 | 32.57 | 22.96 |
Diluted EPS Before Non-Recurring Items | -1.91 | -2.35 | -2.06 | -2.00 | -2.43 |
Diluted Net EPS (GAAP) | -1.78 | -2.35 | -2.29 | -0.99 | -2.43 |
Fiscal Year end for Sutro Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 13.01 | 113.72 | 16.92 | 10.41 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 13.01 | 113.72 | 16.92 | 10.41 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 69.60 | 70.57 | 60.94 | 56.59 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -56.59 | 43.15 | -44.02 | -46.18 |
Non-Operating Income | NA | -1.62 | 11.47 | -3.43 | 8.25 |
Interest Expense | NA | 0.00 | 7.75 | 0.00 | 0.44 |
Pretax Income | NA | -58.21 | 46.87 | -47.45 | -38.37 |
Income Taxes | NA | 0.00 | 15.81 | 1.84 | 0.15 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -58.21 | 31.07 | -49.28 | -38.52 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -58.21 | 31.07 | -49.28 | -38.52 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 61.46 | 59.74 | 60.60 | 60.34 |
Diluted EPS Before Non-Recurring Items | NA | -0.95 | 0.42 | -0.81 | -0.64 |
Diluted Net EPS (GAAP) | NA | -0.95 | 0.52 | -0.81 | -0.64 |